glp-1 news today october 2025 health pharma obesity drugs Outlook for obesity in 2025: more Beyond GLP-1: the next wave
Description
Maintaining weight loss after stopping a medication like GLP-1 can be challenging, but with the righ
In this post, Ill share with you some of the plotline for our discussion
Sliding Scale GLP-1 is a virtual telehealth programdesigned so everyone can access expert support
On August 28, 2024, Eli Lilly and Company submitted anominationto request that its GLP-1 product, tirzepatide, be added to FDAs Demonstrable Difficulties for Compounding (DDC) lists.
Susan Maria is back
